Study identifier:1033IL/0039
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomised, double-blind, study comparing ARIMIDEX™ with NOLVADEX™ as neo-adjuvant and adjuvant treatment in post-menopausal women with large operable (T2 (≥3cm), T3, N0-2, M0) or potentially-operable, locally advanced (T4b, N0-2, M0), ER+ and/or PR+ breast cancer.
Breast Cancer
Phase 3
No
ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
Female
452
Interventional
60 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated. The main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects the extent of surgery that is required.
Location
Location
Antwerpen, Belgium
Location
Hasselt, Belgium
Location
Leuven, Belgium
Location
Liege, Belgium
Location
Rio de Janeiro, RJ, Brazil
Location
Porto Alegre, RS, Brazil
Location
São Paulo, SP, Brazil
Location
Fortaleza, Brazil
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.